Authors


Ariela Marshall, MD

Latest:

Female Representation in Clinical Practice Guideline Panels in 2 Major Cancer Organizations

Although female representation for National Comprehensive Cancer Network guidelines has increased to at least 50%, participation in guideline panels across all organizations is still less than 30%.


Yang Wang, MBBS

Latest:

Profilin 1 Protein and Its Implications for Cancers

Profilin 1, or PFN1, is a key actin-binding protein that is involved in various cellular activities, such as cell motility, survival, and membrane trafficking. By summarizing the functions of PFN1 in cancer, investigators hope to better understand the mechanisms of PFN1 in cancer progression.



Carlos Hernández Terciado, PharmG

Latest:

Effectiveness, Toxicity, and Survival Predictors of Regorafenib in Metastatic Colorectal Cancer: A Multicenter Study of Routinely Collected Data

Alberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.


Rachel Rau, MD

Latest:

Pediatric-Inspired Asparaginase Regimens for Patients With Acute Lymphocytic Leukemia

Rachel Rau, MD, gives her perspective on the use of asparaginase treatments for pediatric patients with acute lymphocytic leukemia.


Hannah Palmer, AGNP

Latest:

Patient-Centered Approaches in EGFR-Mutated NSCLC

Panelists discuss how oral and subcutaneous therapies have improved the quality of life for patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC), with Squires sharing patient benefits from newer administration routes, and Dr Scott highlighting promising developments in EGFR-mutated NSCLC treatments, while exploring the evolving role of patient empowerment, self-management, and the multidisciplinary care team in supporting patients through home-based care and active participation in their treatment journey.


Keith Hecht, PharmD

Latest:

Expert Commentary on the Product Profile of Loncastuximab Tesirine

In an interview with ONCOLOGY®, Keith Hecht, PharmD, offers a comprehensive review of real-world treatment considerations of loncastuximab tesirine as therapy for patients with diffuse large B-cell lymphoma.


Takayuki Yoshino, MD, PhD

Latest:

COLOMATE Challenge to Overcome Resistance in Metastatic Colorectal Cancer

Takayuki Yoshino, MD, PhD gives his perspective on the COLMATE trial and what it's done to help patients overcome colorectal cancer.



John Shanahan, BA

Latest:

The Negative Impact of the COVID-19 Pandemic on Oncology Care at an Academic Cancer Referral Center

COVID-19 created unexpected delays in oncologic treatment. This study sought to assess the volume of missed cancer-related services due to the pandemic.


Divya Asti, MD

Latest:

Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials

The aim of this meta-analysis is to analyze the efficacy of these drugs in the treatment of mCRPC in terms of progression-free survival (PFS) and overall survival (OS), using the results of completed trials.


Jessica Hergert

Latest:

Survival Boost Noted With Addition of Durvalumab to Chemotherapy for BTC

When compared with placebo and chemotherapy, durvalumab plus gemcitabine and cisplatin was superior in terms of overall survival in the treatment of advanced biliary tract cancer.




Evelyn Lilian Beas-Lozano, MD

Latest:

Hereditary Renal Tumor Syndromes and the Use of mTOR Inhibitors

A 47-year-old woman with a history of drug-resistant epilepsy during childhood presented to the emergency department with sudden dyspnea and chest pain. Upon admission, her oxygen saturation was 88%.






Matthew T. Campbell, MD, MS

Latest:

Scratching the Surface in Managing Advanced RCC

Matthew T. Campbell, MD, MS, discusses CAR T-cell therapy and immunotherapy advances in renal cell carcinoma.


Murali Janakiram, MD, MS

Latest:

CARTITUDE-4 Study: Cilta-Cel vs Standard of Care for Lenalidomide-Refractory Multiple Myeloma

Panelists review the CARTITUDE-4 study results highlighting the efficacy of cilta-cel in lenalidomide-refractory multiple myeloma, addressing implementation challenges and patient preferences in varying relapse scenarios.




Karen H. Lu, MD

Latest:

Karen H. Lu, MD, on Next Steps in Evaluating Genetic Testing in Underrepresented Minorities

The MD Anderson Cancer Center expert discussed further research in delivering online accessible genetic testing.


Eileen O’Reilly, MD

Latest:

Treatment Paradigm for Early-Stage Pancreatic Cancer Diagnosis

With Eileen O’Reilly, MD, the Oncology Brothers discuss the current treatment paradigm for early-stage pancreatic cancer, focusing on diagnostic strategies, surgical options, and adjuvant therapies to improve patient outcomes.


Mariana Licano-Zubiate, MD

Latest:

Metastatic Renal Cell Carcinoma With Sarcomatoid Features

In this installement of Clinical Quandaries, Abigail Mateos-Soria, MD, and colleagues present a case of an 38-year-old woman who has a 3-month history of fatigue, dyspnea, significant weight loss, and severe left flank pain.



Jeffrey M. Ryckman, MD

Latest:

Adverse Effects Associated with SBRT in Patients With HCC

The panel discusses adverse effects associated with stereotactic body radiation therapy, and the Oncology Brothers provide a recap of the entire discussion.



Anjali Hari, MD

Latest:

Anjali Hari, MD, Highlights the Rationale for Assessing HIPEC in Frail and Non-Frail Ovarian Cancer

Anjali Y. Hari, MD, speaks to the rationale for examining hyperthermic intraperitoneal chemotherapy in a population of frail and non-frail patients with ovarian cancer.